









Markets
/
Stocks
/
nasdaq-abvc
/

ABVC Biopharma Inc

ABVC

1.740USD

+0.140+8.75%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

42.09MMarket Cap

LossP/E TTM



ABVC Biopharma Inc

1.740

+0.140+8.75%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ABVC Biopharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

ABVC Biopharma Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 206 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ABVC Biopharma Inc's Score

Industry at a Glance

Industry Ranking

206 / 392

Overall Ranking

401 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

ABVC Biopharma Inc Highlights

StrengthsRisks

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.

Growing

The company is in a growing phase, with the latest annual income totaling USD 509.59K.

Undervalued

The company’s latest PE is -6.21, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 287.94K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of ABVC Biopharma Inc is 7.88, ranking 71 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 795.95K, representing a year-over-year increase of 104.47%, while its net profit experienced a year-over-year increase of 568.15%.

Score

Industry at a Glance

Previous score

7.88

Change



Financials

5.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.02

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.60

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.52

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ABVC Biopharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of ABVC Biopharma Inc is 6.89, ranking 205 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.21, which is -96.34% below the recent high of -0.23 and -199.55% above the recent low of -18.59.

Score

Industry at a Glance

Previous score

6.89

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 206/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for ABVC Biopharma Inc. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of ABVC Biopharma Inc is 6.45, ranking 243 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.18 and the support level at 1.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.17

Change

0.28

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.056

Sell

RSI(14)

34.982

Neutral

STOCH(KDJ)(9,3,3)

26.660

Neutral

ATR(14)

0.132

Low Volatility

CCI(14)

-152.396

Sell

Williams %R

68.657

Sell

TRIX(12,20)

-0.676

Sell

StochRSI(14)

90.902

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.806

Sell

MA10

1.929

Sell

MA20

2.007

Sell

MA50

2.188

Sell

MA100

2.558

Sell

MA200

2.450

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of ABVC Biopharma Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.34%, representing a quarter-over-quarter decrease of 3.13%. The largest institutional shareholder is The Vanguard, holding a total of 287.94K shares, representing 1.12% of shares outstanding, with 208.46% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Jiang (Shuling)

1.00M

+3.82%

YuanGene, Corp

829.70K

Jiang (Tsung-Shann)

375.99K

-11.15%

The Vanguard Group, Inc.

Star Investors

267.45K

+139.79%

Geode Capital Management, L.L.C.

187.81K

+69.97%

Jiang (Eugene)

131.16K

Renaissance Technologies LLC

Star Investors

110.50K

+164.95%

State Street Investment Management (US)

72.80K

+464.34%

Patil (Uttam)

72.43K

Odaira (Yoshinobu)

57.76K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ABVC Biopharma Inc is 3.01, ranking 178 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.